Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
24
Bone marrow evaluation plays a critical role in staging and predicting prognosis in patients with Hodgkin lymphoma or non-Hodgkin lymphoma, researchers in the United States report.
17
New research, 'Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting,' is the subject of a report.
15
Merck Frosst has announced today the approval in Canada of a first of its class in cancer treatment, (Pr)ZOLINZA(TM) (vorinostat capsules) for advanced CTCL (cutaneous T-cell lymphoma), a rare form of non-Hodgkins lymphoma which affects mainly the skin. The launch of ZOLINZA(TM) (vorinostat capsules) is part of the Merck Frosst commitment to the development of products to prevent cancer, to treat cancer and to provide supportive care to cancer patients.
14
The cure rates for many cancers have improved dramatically over the past decades, but the harsh reality is that too many cancer survivors suffer serious side-effects of their curative treatments. Toxic side-effects can occur months or years after the treatments are finished, sometimes as chronic conditions, sometimes life- threatening, but always unacceptably reducing a patient's quality of life.
10
New investigation results, 'Management of relapsed mantle cell lymphoma: still a treatment challenge,' are detailed in a study published in ONCOLOGY. Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma that remains incurable, and is associated with a median survival of approximately 5 years. Management of patients with relapsed or refractory disease is challenging, investigators in the United States report.
04
Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN(R) (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S. Food and Drug Administration (FDA) for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.
03
Two of the most powerful approaches to cancer treatment -- a stem cell transplant and an immune system-stimulating vaccine -- appear to reinforce each other in patients with an aggressive, hard-to-control form of leukemia, Dana-Farber Cancer Institute scientists have found.
27
In this recent report published in the journal Occupational and Environmental Medicine, researchers in the United States conducted a study To investigate the relationship between selected solvent-related workplace tasks (degreasing, painting, gluing, stripping paint, staining) and risk of non-Hodgkin lymphoma (NHL). We analysed occupational data from a large population-based case-control study of NHL conducted in the USA.
Scientists discuss in 'The future of small molecule inhibitors in lymphoma' new findings in lymphoma. For the many patients with lymphoma that has relapsed after and/or has become refractory to existing treatments, the development of novel therapeutics is imperative. Investigation into intracellular processes that are dysregulated during lymphomagenesis has uncovered several new potential targets for anticancer agents, investigators in the United States report.
The interaction of multiple myeloma (MM) cells with the bone marrow (BM) milieu plays a crucial role in MM pathogenesis. Stromal cell-derived factor-1 (SDF1) regulates homing of MM cells to the BM,
We care about your feedback. Let us know how we can improve your CancerCompass experience.